Last reviewed · How we verify
Naltrexone Tablet and Placebo Patch
Naltrexone Tablet and Placebo Patch is a Opioid receptor antagonist Small molecule drug developed by The Scripps Research Institute. It is currently FDA-approved for Opioid use disorder, Alcohol use disorder. Also known as: Revia.
Naltrexone blocks opioid receptors to reduce cravings and reward-seeking behavior, while the placebo patch serves as a control in this combination formulation.
Naltrexone is a medication used to treat conditions such as alcoholism and smoking, as indicated by studies on ClinicalTrials.gov. It is administered in the form of a tablet, and has been studied in combination with a placebo patch, among other interventions.
At a glance
| Generic name | Naltrexone Tablet and Placebo Patch |
|---|---|
| Also known as | Revia |
| Sponsor | The Scripps Research Institute |
| Drug class | Opioid receptor antagonist |
| Target | Mu, delta, and kappa opioid receptors |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Naltrexone is an opioid antagonist that competitively binds to mu, delta, and kappa opioid receptors, preventing endogenous and exogenous opioids from activating these receptors. This mechanism reduces the reinforcing effects of opioids and decreases cravings in opioid use disorder. The placebo patch component suggests this was studied as part of a controlled trial design.
Approved indications
- Opioid use disorder
- Alcohol use disorder
Common side effects
- Nausea
- Headache
- Anxiety
- Insomnia
- Hepatotoxicity (at high doses)
Key clinical trials
- The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers (PHASE1)
- Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naltrexone Tablet and Placebo Patch CI brief — competitive landscape report
- Naltrexone Tablet and Placebo Patch updates RSS · CI watch RSS
- The Scripps Research Institute portfolio CI
Frequently asked questions about Naltrexone Tablet and Placebo Patch
What is Naltrexone Tablet and Placebo Patch?
How does Naltrexone Tablet and Placebo Patch work?
What is Naltrexone Tablet and Placebo Patch used for?
Who makes Naltrexone Tablet and Placebo Patch?
Is Naltrexone Tablet and Placebo Patch also known as anything else?
What drug class is Naltrexone Tablet and Placebo Patch in?
What development phase is Naltrexone Tablet and Placebo Patch in?
What are the side effects of Naltrexone Tablet and Placebo Patch?
What does Naltrexone Tablet and Placebo Patch target?
Related
- Drug class: All Opioid receptor antagonist drugs
- Target: All drugs targeting Mu, delta, and kappa opioid receptors
- Manufacturer: The Scripps Research Institute — full pipeline
- Therapeutic area: All drugs in Addiction Medicine / Psychiatry
- Indication: Drugs for Opioid use disorder
- Indication: Drugs for Alcohol use disorder
- Also known as: Revia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing